Literature DB >> 23154748

Aggressive B-cell lymphomas: how many categories do we need?

Jonathan W Said1.   

Abstract

Aggressive B-cell lymphomas are diverse group of neoplasms that arise at different stages of B-cell development and by various mechanisms of neoplastic transformation. The aggressive B-cell lymphomas include many types, subtypes and variants of diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), mantle cell lymphoma and its blastoid variant, and B lymphoblastic lymphoma. Differences in histology, cytogenetic and molecular abnormalities, as well as the relationship with the tumor microenvironment, help define characteristic signatures for these neoplasms, and in turn dictate potential therapeutic targets. Rather than survey the entire spectrum of aggressive B-cell lymphomas, this report aims to identify and characterize important clinically aggressive subtypes of DLBCL, and explore the relationship of DLBCL to BL and the gray zone between them (B-cell lymphoma unclassifiable with features intermediate between DLBCL and BL).

Entities:  

Mesh:

Year:  2012        PMID: 23154748      PMCID: PMC4406768          DOI: 10.1038/modpathol.2012.178

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  72 in total

1.  B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome.

Authors:  Shaoying Li; Pei Lin; Luis E Fayad; Patrick A Lennon; Roberto N Miranda; C Cameron Yin; E Lin; L Jeffrey Medeiros
Journal:  Mod Pathol       Date:  2011-10-14       Impact factor: 7.842

2.  Cyclin D1 positive diffuse large B-cell lymphoma is a post-germinal center-type lymphoma without alterations in the CCND1 gene locus.

Authors:  Teresa Vela-Chávez; Patrick Adam; Marcus Kremer; Karin Bink; Christopher M Bacon; Geetha Menon; Judith A Ferry; Falko Fend; Elaine S Jaffe; Leticia Quintanilla-Martínez
Journal:  Leuk Lymphoma       Date:  2011-02-01

3.  Geographic variation in the prevalence of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly: a comparative analysis of a Mexican and a German population.

Authors:  Annegret Hofscheier; Ana Ponciano; Irina Bonzheim; Patrick Adam; Carmen Lome-Maldonado; Teresa Vela; Evelyn Cortes; Carlos Ortiz-Hidalgo; Falko Fend; Leticia Quintanilla-Martinez
Journal:  Mod Pathol       Date:  2011-04-15       Impact factor: 7.842

Review 4.  Primary lymphoma of the central nervous system: just DLBCL or not?

Authors:  Manuel Montesinos-Rongen; Reiner Siebert; Martina Deckert
Journal:  Blood       Date:  2008-09-18       Impact factor: 22.113

5.  Prognostic value of MYC rearrangement in cases of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma.

Authors:  Pei Lin; Timothy J Dickason; Luis E Fayad; Patrick A Lennon; Peter Hu; Mar Garcia; Mark J Routbort; Roberto Miranda; Xumei Wang; Wei Qiao; L Jeffrey Medeiros
Journal:  Cancer       Date:  2011-08-31       Impact factor: 6.860

6.  The proportion of activated B-cell like subtype among de novo diffuse large B-cell lymphoma increases with age.

Authors:  Sylvain Mareschal; Hélène Lanic; Philippe Ruminy; Christian Bastard; Hervé Tilly; Fabrice Jardin
Journal:  Haematologica       Date:  2011-08-22       Impact factor: 9.941

Review 7.  B-cell lymphomas with features intermediate between distinct pathologic entities. From pathogenesis to pathology.

Authors:  Antonino Carbone; Annunziata Gloghini; Antonella Aiello; Adele Testi; Antonello Cabras
Journal:  Hum Pathol       Date:  2010-05       Impact factor: 3.466

8.  Simultaneous aberrations of single CDKN2A network components and a high Rb phosphorylation status can differentiate subgroups of primary cutaneous B-cell lymphomas.

Authors:  Kjell M Kaune; Christine Neumann; Christian Hallermann; Florian Haller; Michael P Schön; Peter Middel
Journal:  Exp Dermatol       Date:  2011-04       Impact factor: 3.960

9.  Aggressive large B-cell lymphoma with plasma cell differentiation: immunohistochemical characterization of plasmablastic lymphoma and diffuse large B-cell lymphoma with partial plasmablastic phenotype.

Authors:  Santiago Montes-Moreno; Ana-Rosa Gonzalez-Medina; Socorro-María Rodriguez-Pinilla; Lorena Maestre; Lydia Sanchez-Verde; Giovanna Roncador; Manuela Mollejo; Juan F García; Javier Menarguez; Carlos Montalbán; M Carmen Ruiz-Marcellan; Eulogio Conde; Miguel A Piris
Journal:  Haematologica       Date:  2010-04-23       Impact factor: 9.941

10.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.

Authors:  Christine P Hans; Dennis D Weisenburger; Timothy C Greiner; Randy D Gascoyne; Jan Delabie; German Ott; H Konrad Müller-Hermelink; Elias Campo; Rita M Braziel; Elaine S Jaffe; Zenggang Pan; Pedro Farinha; Lynette M Smith; Brunangelo Falini; Alison H Banham; Andreas Rosenwald; Louis M Staudt; Joseph M Connors; James O Armitage; Wing C Chan
Journal:  Blood       Date:  2003-09-22       Impact factor: 22.113

View more
  18 in total

1.  Diagnostic Dilemmas in Aggressive Large B Cell Neoplasms with Enigmatic Immunohistochemical Profile: How Far Should We Investigate?

Authors:  Neha Singh; Sunil Pasricha; Narendra Agrawal; Jatin S Gandhi; Ajit Panaych; Anurag Mehta; Rayaz Ahmed; Dinesh Bhurani
Journal:  Indian J Hematol Blood Transfus       Date:  2017-06-15       Impact factor: 0.900

2.  Development and Characterization of 3D Hybrid Spheroids for the Investigation of the Crosstalk Between B-Cell Non-Hodgkin Lymphomas and Mesenchymal Stromal Cells.

Authors:  Kamila Duś-Szachniewicz; Katarzyna Gdesz-Birula; Grzegorz Rymkiewicz
Journal:  Onco Targets Ther       Date:  2022-06-17       Impact factor: 4.345

3.  Clinical diagnostic dilemma in an uncharacteristic rapidly enlarging swelling of the anterior maxilla: extranodal diffuse large B cell lymphoma.

Authors:  Cheriyanthal Sisupalan Jayapalan; Meera Kunjumon Pynadath; Ummar Mangalath; Antony George; Sachin Aslam; Abdul Hafiz
Journal:  BMJ Case Rep       Date:  2016-03-30

4.  B-cell-specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in mice.

Authors:  Gero Knittel; Paul Liedgens; Darya Korovkina; Jens M Seeger; Yussor Al-Baldawi; Mona Al-Maarri; Christian Fritz; Katerina Vlantis; Svetlana Bezhanova; Andreas H Scheel; Olaf-Oliver Wolz; Maurice Reimann; Peter Möller; Cristina López; Matthias Schlesner; Philipp Lohneis; Alexander N R Weber; Lorenz Trümper; Louis M Staudt; Monika Ortmann; Manolis Pasparakis; Reiner Siebert; Clemens A Schmitt; Andreas R Klatt; F Thomas Wunderlich; Stephan C Schäfer; Thorsten Persigehl; Manuel Montesinos-Rongen; Margarete Odenthal; Reinhard Büttner; Lukas P Frenzel; Hamid Kashkar; H Christian Reinhardt
Journal:  Blood       Date:  2016-04-05       Impact factor: 22.113

5.  Multiparameter analysis of homogeneously R-CHOP-treated diffuse large B cell lymphomas identifies CD5 and FOXP1 as relevant prognostic biomarkers: report of the prospective SAKK 38/07 study.

Authors:  Alexandar Tzankov; Nora Leu; Simone Muenst; Darius Juskevicius; Dirk Klingbiel; Christoph Mamot; Stephan Dirnhofer
Journal:  J Hematol Oncol       Date:  2015-06-14       Impact factor: 17.388

6.  (-)-Epigallocatechingallate induces apoptosis in B lymphoma cells via caspase-dependent pathway and Bcl-2 family protein modulation.

Authors:  Jiangyan Wang; Yu'an Xie; Yan Feng; Litu Zhang; Xinping Huang; Xiaoyun Shen; Xiaoling Luo
Journal:  Int J Oncol       Date:  2015-02-03       Impact factor: 5.650

7.  B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Burkitt's lymphoma: A case report and review.

Authors:  Tabita Joy Chettiankandy; Jagdish Vishnu Tupkari; Keshav Kumar; Manisha Sandeep Ahire
Journal:  J Oral Maxillofac Pathol       Date:  2016 May-Aug

8.  Collapsin response mediator protein 4 promotor methylation level as a potential predictor for diagnosing primary malignant lymphoma of the prostate.

Authors:  Zheng Chen; Qiong Liang; Jue Wang; Qun-Xiong Huang; Jian-Ning Chen; Zi-Jin Weng; Chun-Kui Shao; Xin Gao; Jun Pang
Journal:  Cancer Cell Int       Date:  2018-01-04       Impact factor: 5.722

Review 9.  Aggressive lymphoma 2016: revision of the WHO classification.

Authors:  Christine Beham-Schmid
Journal:  Memo       Date:  2017-11-30

Review 10.  Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapy.

Authors:  Antonino Carbone; Annunziata Gloghini; Yok-Lam Kwong; Anas Younes
Journal:  Ann Hematol       Date:  2014-05-29       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.